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ABSTRACT
Background. Malignant peritoneal mesothelioma (MPM)
is a rare and aggressive disease. Recently, focus has shifted
toward a more aggressive and multimodal treatment
approach. This study aimed to assess the patterns of care
and survival for MPM patients in the Netherlands on a
nationwide basis.
Methods. The records of patients with a diagnosis of
MPM from 1993 to 2016 were retrieved from the Dutch
Cancer Registry. Data regarding diagnosis, staging, treat-
ment, and survival were extracted. Cox regression analyses
and Kaplan–Meier survival curves were used to study
overall survival.
Results. Between 1993 and 2016, MPM was diagnosed for
566 patients. Overall, the prognosis was very poor (24%
1-year survival). The most common morphologic subtype
was the epithelioid subtype (88%), followed by the
biphasic (8%) and sarcomatoid (4%) subtypes. Surgical
treatment has become more common in recent years, which
most likely has resulted in improved survival rates. In this
study, improved survival was independently associated
with hyperthermic intraperitoneal chemotherapy (hazard
ratio [HR], 0.33; 95% confidence interval [CI], 0.21–0.55)
and surgery with adjuvant systemic chemotherapy (HR,
0.33; 95% CI, 0.23–0.48). Nonetheless, most patients
(67%) do not receive any form of anti-cancer treatment.
Conclusion. This study indicated that MPM still is a rare
and fatal disease. The survival rates in the Netherlands
have improved slightly in the past decade, most likely due
to more aggressive treatment approaches and increased use
of surgery. However, most patients still do not receive
cancer-directed treatment. To improve MPM management,
and ultimately survival, care should be centralized in
expert medical centers.
Malignant peritoneal mesothelioma (MPM) is a rare and
aggressive neoplasm arising from the serosal lining of the
abdominal cavity.1 It represents about 10–15% of all
malignant mesothelioma cases, making it the second most
common location.2 Pleural mesothelioma is far more
common, representing more than 80% of cases. Other,
more rare, locations are the pericardium (\ 1%) and the
tunica vaginalis of the testis (\ 1%). The main risk factor
for the development of malignant mesothelioma is asbestos
exposure.3
Generally, MPM is predominantly known as a locally
aggressive tumor. Malignant ascites and locoregional
invasion cause morbidity and mortality, whereas metastatic
lymph nodes (5–10%) and extraabdominal disease (3–5%)
are rare. Patients experience nonspecific symptoms such as
nausea, abdominal pain, weight loss, and abdominal dis-
tension.4 Accordingly, diagnosing MPM is difficult and
often delayed. As a result, MPM is mostly diagnosed when
patients are in an advanced stage of the disease, leading to
poor survival rates even after extensive treatment.5
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Due to the rarity of MPM, little is known about the
epidemiology and treatment patterns on a nationwide basis.
Also, no randomized studies comparing outcomes of dif-
ferent treatment strategies are available, implying the need
for large retrospective cohort studies. Therefore, in this
study, MPM incidence, patterns of care, and survival on a
population-based level in the Netherlands were investi-
gated during a 24-year period.
METHODS
Collection of Data
Data on patients with MPM diagnosed from 1993
through 2016 were retrieved from the Netherlands Cancer
Registry (NCR) after formal approval by the NCR Moni-
toring Committee. The NCR collects data on all patients
with cancer diagnosed in the Netherlands based on notifi-
cation of newly diagnosed malignancies by the national
automated pathologic archive and on hospital discharge
diagnoses. Information on diagnosis, staging, and treatment
is extracted routinely from the medical records by specially
trained NCR personnel. Information on survival status is
updated annually using a computerized link with the
national civil registry. For the current analysis, survival
information was updated to 1 February 2019. Cause of
death was not available due to privacy regulations.
Stage information was recorded according to the
Surveillance Epidemiology and End Results (SEER) extent
of disease (EOD) classification, distinguishing local,
regional, and distant progression. Local disease is confined
to the peritoneum, whereas regional disease comprises
contiguous growth to adjacent organs or extension to
regional lymph nodes. Distant progression may include
invasion of intraabdominal organs.
For the most recent period, between 2009 and 2016,
information on the site of distant metastases was available.
Tumor site and histologic subtype were recorded according
to the topography and morphology codes of the Interna-
tional Classification of Diseases for Oncology (ICD-O-3).
Since 2000, all suspected cases of malignant mesothe-
lioma in the Netherlands are reviewed by the Dutch
National Mesothelioma Panel (NMP), a group of expert
pathologists and (pulmonary) oncologists.6,7 Their review
process is primarily based on pathology, but when no
material is available for review or no definite diagnosis can
be made, the case is reviewed by three independent clini-
cians specialized in mesothelioma. At least two of the three
specialists must independently confirm the diagnosis.
Before 2000, this expert review was not performed sys-
tematically, but a similar panel of specialists has been
available since 1972 to advise in diagnosing
mesothelioma.8 Treatment information comprises coding
for resection surgery, systemic chemotherapy, and local
(intraperitoneal) chemotherapy.
Unfortunately, specifics regarding type of surgery,
extent of cytoreduction, type of chemotherapy, and number
of cycles were not available. Data about comorbidity or
performance status also were not available. Asbestos
exposure was not reported in the national registry.
The Netherlands comprises 92 hospitals, and cytore-
ductive surgery (CRS) with hyperthermic intraperitoneal
chemotherapy (HIPEC) is performed in nine centers.
During the entire period of this study, the country’s pop-
ulation grew from 15.5 million to 16.7 million inhabitants.
Statistical Analyses
The Kaplan–Meier method was used for survival anal-
ysis, and comparisons between groups were made using
log-rank test. Overall survival was calculated from the date
of diagnosis until death or last follow-up visit. Patients
were censored when alive at the last follow-up date.
Treatment patterns were tabulated by period of diagnosis
and evaluated with Chi square analyses. Multivariable Cox
proportional hazards models were constructed to identify
prognostic factors, and hazard ratios (HRs) with 95%
confidence intervals (CIs) for these factors were calculated.
Nonsignificant prognostic factors were excluded from the
model using backward elimination. Two-sided p values
lower than 0.05 were considered statistically significant.
Statistical analyses were performed using STATA version
14 (StataCorp 2015. Stata Statistical Software: Release 14;
StataCorp LP, College Station, TX, USA). Figures were
made using R version 3.5.1 (http://www.r-project.org) and
GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego, CA USA; www.graphpad.com).
RESULTS
Patient Characteristics
During the study period, MPM was diagnosed for 566
patients: 420 men (74%) and 146 women (26%) (Table 1).
The median age at diagnosis was 69 years (interquartile
range [IQR], 62–76 years) for the men and 65 years (IQR,
54–75 years) for the women.
The stage of disease was available for 74% of the cases.
Local disease was reported in 30% of the cases, and in 24%
of the cases, MPM had spread regionally. Distant pro-
gression was seen in 20% of the patients.
More detailed information regarding metastatic sites
was available only for the latest period, between 2009 and
2016. During this period, distant progression according to
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the EOD classification was reported for 23.4% of the
patients. Of these metastases, 42.5% were located
intraabdominally, and 20% were lymph node metastases
whose exact location was not specified. Therefore the true
percentage of cases in which the disease had spread outside
the abdominal cavity was between 8.8 and 13.5%. The
extraabdominal metastatic sites were the pleura (7.6%) and
the lung (2.3%).
Information about histopathologic subtype was available
for 65% of the patients. Most frequently observed was the
epithelioid subtype, in 89% of the cases, followed by the
biphasic subtype in 8% and the sarcomatoid subtype in 4%.
The diagnosis was based on histology in 89% of the cases
and on cytology in 11% of the cases. In 35% of the cases,
the histopathologic subtype was not specified in the
pathology report and therefore not registered.
Treatment Patterns
To evaluate patterns of care over time, the data were
stratified into three periods: period 1 (1993–2000), period 2
(2001–2008), and period 3 (2009–2016). The treatment
patterns are depicted in Fig. 1, and the corresponding
survival per period is shown in Table 1 and Fig. 2. The use
of systemic chemotherapy without surgery increased over
time, from 16% in period 1 to 26% in period 3.
In the most recent years, treatment strategies have been
more aggressive, with increased use of surgery in combi-
nation with local or systemic chemotherapy. The use of
intraperitoneal chemotherapy increased, from 2% of the
patients in periods 1 and 2 to 10% in period 3. Combination
of surgery with systemic chemotherapy decreased in the
latest years, from 12% between 2001 and 2008 to 4%
TABLE 1 Patient characteristics
Subjects
n (%)a
Median survival
Months (IQR)
1-Year survival (%) 2-Year survival (%) p value
Overall 566 (100) 4.5 (1.5–11.6) 24 15 –
Gender
Men 420 (74) 3.6 (1.3–8.1) 17 10 \ 0.001
Women 146 (26) 8.9 (2.8–33.1) 45 30
Age (years)
0–64 197 (35) 7.3 (2.7–26.6) 40 27 \ 0.001
65–74 199 (35) 4.6 (1.7–9.5) 19 11
75? 170 (30) 1.9 (0.9–6.9) 12 6
EOD stage
Local 172 (30) 5.4 (1.8–14.9) 28 17 0.102
Regional 136 (24) 5.0 (1.4–12.2) 26 15
Distant 111 (20) 3.6 (1.1–10.8) 20 14
Unknown 147 (26) 3.1 (1.5–9.9) 20 14
Period
1993–2000 166 (29) 4.5 (1.4–7.7) 17 10 0.02
2001–2008 195 (34) 3.8 (1.5–11.3) 23 13
2009–2016 205 (36) 5.0 (1.6–18.6) 31 20
Morphology
Epithelioid 324 (57) 5.0 (1.2–8.0) 27 18 0.02
Sarcomatoid 14 (2) 2.0 (1.1–12.0) 29 14
Biphasic 31 (5) 3.4 (1.8–14.9) 13 9
NOS 197 (35) 3.6 (1.2–8.1) 20 11
Therapy
Chemotherapy 117 (21) 8.8 (5.0–17.1) 36 18 \ 0.001
Surgery ± chemo 43 (8) 15.5 (4.7–67.1) 56 44
HIPEC ± CRS 28 (5) 23.4 (6.9–83.6) 68 50
Other/BSC 378 (67) 2.5 (1.1–6.7) 13 8
IQR interquartile range, EOD extent of disease classification, NOS not otherwise specified, HIPEC hyperthermic intraperitoneal chemotherapy,
CRS cytoreductive surgery
aPercentages in the subjects column do not add up to 100% due to rounding
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between 2009 and 2016. The percentage of patients who
did not receive any cancer-directed treatment declined
gradually over the years, from 75 to 60%. This group
however still comprises the majority of patients.
Survival
Overall survival improved over time, with better sur-
vival between 2009 and 2016 than between 1993 and 2000
(p = 0.023) (Fig. 2). It was suggested that this could be an
effect of treatment trends. Therefore, treatment strategies
were included in the multivariable analysis. Better survival
was independently associated with surgery (HR, 0.33; 95%
CI, 0.23–0.48), HIPEC (HR, 0.33; 95% CI, 0.21–0.55), and
systemic chemotherapy (HR, 0.61; 95% CI, 0.49–0.76)
(Table 2). Female sex also was associated with better
survival (HR, 0.65; 95% CI, 0.53–0.81). Age of
65–74 years at the time of diagnosis (HR, 1.55; 95% CI,
1.25–1.92) and age older than 75 years (HR, 2.00; 95% CI,
1.59–2.51) was independently associated with diminished
survival outcome. Significantly worse survival was asso-
ciated with the sarcomatoid (HR, 1.23; 95% CI, 0.70–2.15),
biphasic (HR, 1.54; 95% CI, 1.05–2.26), and undefined
morphologic (HR, 1.26; 95% CI, 1.05–1.52) subtypes.
DISCUSSION
This study provides insight into the epidemiology and
changes in patterns of MPM treatment on a nationwide
basis in the Netherlands. Analyzing data retrieved from the
NCR showed that MPM is a rare disease and that prognosis
still is very poor. Patients eligible to undergo surgery,
HIPEC, or both have significantly better median survival
rates than patients receiving systemic chemotherapy or best
supportive care. Although an increasing percentage of
patients receive anti-cancer therapy, the majority of
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TABLE 2 Multivariable survival analysis
HR 95% CI p value
Gender
Men 1
Women 0.65 0.53–0.81 \ 0.001
Age (years)
0–64 1
65–74 1.55 1.25–1.92 \ 0.001
C 75 2.00 1.59–2.51 \ 0.001
Morphology
Epithelial 1
Sarcomatoid 1.23 0.70–2.15 0.476
Biphasic 1.54 1.05–2.26 0.027
NOS 1.26 1.05–1.52 0.012
Therapy
BSC/other 1
Chemotherapy alone 0.61 0.49–0.76 \ 0.001
Surgery ± chemo 0.33 0.23–0.48 \ 0.001
HIPEC ± CRS 0.33 0.21–0.55 \ 0.001
HR hazard ratio, CI confidence interval, NOS not otherwise specified,
BSC best supportive care, chemo systemic chemotherapy, HIPEC
hyperthermic intraperitoneal chemotherapy, CRS cytoreductive
surgery
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patients do not. To achieve better outcome, all patients
should be referred to specialized physicians for evaluation
of their eligibility to undergo surgical treatment.
The patient characteristics found in this study are
comparable with those described in earlier reports.9–14
Women with MPM live longer than men with MPM. It is
sometimes suggested that the better survival among women
is caused by a misdiagnosis of MPM because it has simi-
larities to ovarian cancer. However, in the current cohort,
most of the diagnoses were determined by expert
mesothelioma panels, so this explanation seems unlikely.
What causes better survival among women remains
debated. The fact that women are less often exposed to
asbestos might be favorable for their prognosis because
asbestos exposure has been associated with poor sur-
vival.15,16 Also some studies have reported that higher
cumulative exposure to asbestos results in more aggressive
mesothelioma subtypes.17
A recent study of 16,267 mesothelioma patients by van
Gerwen et al.18 showed significantly more epithelial
mesothelioma in female patients, thereby supporting these
earlier findings. However, after correction for histology and
other prognostic factors, female gender still was indepen-
dently associated with better survival. This finding supports
earlier theories on the protective role of circulating estro-
gen and estrogen receptor-beta expression in
mesothelioma.16,19
Regarding tumor characteristics, morphology was
shown to have prognostic value, but tumor stage was not.
In earlier series, tumor morphology already was identified
to be of prognostic value: the epithelioid subtype has better
survival outcomes than the sarcomatoid or biphasic sub-
type.14 The finding that tumor stage does not seem to
influence survival of MPM patients can be explained by the
lack of an unambiguous staging system. Although efforts
have been made to develop a staging system,20 to date, no
standardized method has been implemented on a interna-
tional level. Therefore, most cases of MPM are not staged
according to a uniform system, which generates heteroge-
neous outcomes between series.9,11–13
This study found that 20% of patients experienced dis-
tant metastases, which is considerably more than in studies
published by Liu et al. and Yan et al.14,20 Before 2009, the
sites of metastases from MPM were not specifically
reported in the Dutch National Cancer Registry. Analysis
of the reported data during the period between 2009 and
2016 showed that metastases occurred in 23.4% of the
cases. However, detailed analysis of the metastatic sites
showed that the percentage of cases with spread of the
disease outside the abdominal cavity was between 8.8%
and 13.5%. These findings suggest that an overestimation
of distant metastases has probably occurred due to the
diffuse growth pattern of MPM. However, other studies
reporting less than 5% distant metastases are mainly sur-
gical series that might underestimate the number of distant
metastases due to preoperative patient selection. Popula-
tion-based series earlier described similar or even higher
numbers of distant metastases.11,21 A uniform staging
system using systematic staging procedures (radiologic and
surgical), is needed for better prognostication.
The influence of various treatment strategies on survival
was statistically evaluated in this analysis. Traditional
treatment options for MPM are (palliative) debulking sur-
gery and systemic chemotherapy. More recently, the focus
has shifted toward CRS–HIPEC, which has shown
encouraging results.22–24 However, even when CRS–
HIPEC is combined with (neo)adjuvant chemotherapy,
progression-free survival is known to be very poor.25–28
In the current cohort, the patients eligible to undergo
surgery (with systemic chemotherapy or CRS–HIPEC)
lived significantly longer than those receiving best sup-
portive care or systemic chemotherapy alone. However,
these data should be interpreted carefully because they
were collected in retrospect. No specific information con-
cerning chemotherapeutic regimens or extent of operative
procedures was available. Also no general staging system
was used in clinical reports.
Differences in survival between treatment strategies are
partly attributable to patient selection. Unfortunately, sur-
vival analysis could not be corrected for patient selection
because no performance score or information about
comorbidities was available. Nonetheless, it seems likely
that improved survival in recent years has been brought
about by the increasing use of surgical treatment strategies.
Although the link between asbestos exposure is not as
strong for peritoneal mesothelioma as for pleural
mesothelioma, up to 60% of patients have been exposed to
asbestos.3,29 Other environmental agents such as zeolite
fibers, a mineral found in volcanic tuff, also have been
associated with mesothelioma development.30 In addition
to environmental agents, other risk factors are germline
BAP1 mutations and other deleterious mutations of tumor
suppressor genes.31,32 All risk factors considered, asbestos
exposure seems to be the largest contributor to MPM risk.
Consequently, because asbestos-related deaths are expec-
ted to keep rising in the coming years,33,34 a pressing need
exists for improvement in MPM management.
An important issue in MPM is the lack of general
methods for diagnosis, staging, and treatment due to the
rarity of the disease. Although patients are more often
treated with aggressive regimens using surgery in combi-
nation with local or systemic chemotherapy, much room
still exists for improvement because the majority of
patients do not receive cancer-directed treatment. Although
a substantial number of patients in the best supportive care
group likely were unfit to undergo treatment due to disease
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burden, comorbidities, or both, it also is probable that a
considerable number of patients in this group were not
treated properly due to a lack of knowledge or expertise.
With the implementation of CRS–HIPEC for MPM
approximately a decade ago in the Netherlands, knowledge
and awareness regarding this treatment option has grown
under specialized physicians. This awareness, however,
seems to trail behind that for other medical specialties.
Surgical treatment options are not generally known,
resulting in delayed referral and treatment. This also was
observed by Miura et al.,21 who suggested that the oppor-
tunity to improve survival with surgical therapy is lost for a
large number of MPM patients in the United States. This
need for awareness can be partly attributed to the lack of
clinical studies.
Recently, the current authors initiated a nationwide
phase 2 clinical trial in the Netherlands, known as the
MESOPEC trial, to assess the feasibility of adjuvant den-
dritic cell-based immunotherapy (DCBI) after CRS–
HIPEC for patients with MPM.35 Earlier, DCBI showed
promising results for patients with pleural mesothe-
lioma.36–38 By simultaneously seeking attention for this
clinical trial and MPM in general, awareness of treatment
possibilities and the number of referrals has increased.
Because CRS–HIPEC can significantly improve survival
for selected candidates, this procedure should be available
for as many patients as possible. This requires expertise in
patient selection and surgical treatment. Accordingly, cen-
tralization of care for MPM patients is of significant
importance for achievement of further improvement in
MPM care and ultimately survival. To achieve this, all
MPM patients should be referred to specialized medical
centers with sufficient knowledge of therapeutic options and
ample experience in performing CRS–HIPEC. Preferably,
these specialized centers are connected to a comprehensive
research facility or university to explore and develop new
therapeutic options for patients with MPM.
Sadly, the MESOPEC trial currently is the only clinical
trial in the European Union exploring new interventions for
patients with MPM. To make a difference and significantly
improve MPM prognosis, expert medical centers should
collaborate to explore new therapeutic options and stan-
dardize treatment strategies.
CONCLUSION
Survival for MPM patients has improved slightly in
recent years, most likely due to more aggressive (multi-
modal) treatment strategies. The majority of MPM patients,
however, do not receive cancer-directed treatment. Con-
siderable progress in MPM management needs to be made
and can be achieved only by centralizing MPM care in
expert centers.
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